Delivery Order SPE2DB22D1106-SPE2DB25FFGF8
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $18,136.65 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of August 22, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $113,263.44 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance to be completed by August 8, 2025, at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $15,904.96 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors. This firm fixed price, non-competitive delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. SKYRIZI is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a $38,306.42 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of SKYRIZI 150 mg/ml pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of August 29, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations for federal...
- The Defense Logistics Agency awarded a delivery order valued at $48,881.85 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors under a firm fixed-price contract type. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. SKYRIZI is a...
- The Defense Logistics Agency awarded a delivery order valued at $31,745.57 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen injectors on July 24, 2025, with completion targeted for July 25, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune and inflammatory conditions, reflecting the federal government's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $25,142.34 for SKYRIZI 150 mg/mL pen injectors on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $21,568.25 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors on August 28, 2025. This firm fixed-price, non-set-aside contract represents a single delivery transaction under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,112.15 for SKYRIZI 150 mg/mL pen injectors under a firm fixed price, non-competitive contract structure. The award was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and performance will be conducted at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite delivery vehicle. This...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFGF8Delivery Order
The Defense Logistics Agency has awarded a delivery order valued at $40,155.43 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside transaction executed on September 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with extensive experience fulfilling DLA requirements across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vehicle enables the company to supply comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally. SKYRIZI, a specialty pharmaceutical for dermatological applications, reflects the company's role in delivering specialized medications across multiple therapeutic domains to federal healthcare customers, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.2k | 9/2/25 |